CONCORD NEWS IN YOUR INBOX: SIGN UP HERE

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

18.23 -0.03 (-0.14%)
Streaming Delayed Price Updated: 10:09 AM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
uniQure N.V. (QURE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
Kaplan Fox Alerts Investors of uniQure N.V. (QURE) to a Securities Class Action Deadline on April 13, 2026
NEW YORK, NY - March 3, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) on behalf... 
Via TheNewswire.com
Topics Lawsuit
uniQure (NASDAQ:QURE) Stock Plummets 40% Despite Earnings Beat on FDA Setback for AMT-130 ↗
Via Chartmill
Topics Earnings
News headline image
Kaplan Fox Alerts Investors of uniQure N.V. (QURE) to a Securities Class Action Deadline on April 13, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE
From Pomerantz LLP
Via GlobeNewswire
News headline image
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP; April 13, 2026, Lead Plaintiff Deadline
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP; April 13, 2026, Lead Plaintiff Deadline
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
These Analysts Cut Their Forecasts On uniQure Following Q4 Results ↗
uniQure (NASDAQ:QURE) reported positive Q4 results, but FDA advised against using data for market application of AMT-130. Stock down 13.3%. 
Via Benzinga
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V.
From Bernstein Liebhard LLP
Via GlobeNewswire
Iran, Dip-Buyers & a Rare Buffett Stumble: Wall Street Shakes Off Its Worst Fears ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
uniQure (QURE) Q4 2025 Earnings Call Transcript ↗
uniQure (QURE) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Get insights into the top gainers and losers of Monday's pre-market session. ↗
Via Chartmill
News headline image
Why Did QURE Stock Almost Halve Pre-Market Today? ↗
uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130. 
Via Stocktwits
News headline image
uniQure Announces 2025 Financial Results and Provides Recent Company Updates
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
uniQure N.V. (QURE) Investors: April 13, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
uniQure N.V. (QURE) Investors: April 13, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? ↗
Analysts are divided on the target, with RBC Capital and Stifel saying the comments appeared to reference uniQure, while Leerink argued they more closely align with Regenxbio’s RGX-121. 
Via Stocktwits
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy ↗
Following the comments, shares of both Regenxbio and uniQure traded in the red. 
Via Stocktwits
Thursday's session: top gainers and losers ↗
Via Chartmill
News headline image
Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? 
Via TheNewswire.com
Topics Fraud Lawsuit
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article